Dr. Julien Edeline (WG3 Co-leader) and team’s project aimed at improving patient outcomes will be funded through 2030

Aimed at improving patient outcomes through the provision of adjuvant targeted therapies (ivosidenib, futibatinib and zanidatamab), the SAFIR IMPACT BTC phase III trial was recently one of two projects awarded funds in the ATTRACT 2025 Call. With this support, supplemented by that of the French INCa and industry partners, Dr. Edeline and his team will be able to launch this study in France, Spain, Italy, Belgium and the Netherlands in late 2026. It is planned to screen about 1000 resected patients to randomize 280 patients whose tumors harbor the targeted alterations.

Accelerate Together Rare Cancer Treatment (ATTRACT) is a charity partnership which brings together five European cancer charities (Anticancer Fund, Fondation ARC, Kom op tegen Kanker, KWF Dutch Cancer Society, and Spanish Association Against Cancer Scientific Foundation) to provide much needed funding for clinical research for rare cancers. This partnership has supported projects to the tune of over €11 million in their 2025 call alone.

The study itself was made possible by the efforts of coordinator Dr. Julien Edeline, and a consortium of collaborators and experts: David Malka, John Bridgewater (WG3), Ivan Borbath, Timon Vandamme (WG3/6), Marjolein Homs, Angela Lamarca (WG3 Co-leader, WG2/4, MC), Lorenza Rimassa (WG3, MC), Anna Saborowski (WG3 Leader, WG6, MC), Arndt Vogel (WG1/2/3/4/5/6), Mia Johansson, Grainne O'Kane (WG2/3/6, MC), Helen Morement (WG4 Co-leader), Lilian Lecorgne (WG3/4/6), Elisabeth Baucels Moreno (WG4), Paolo Leonardi (WG2/4), Lili Anna Kuschnereit, Marta Jimenez, and Daniel Couch.